ArticleJournal of pharmacy & bioallied sciences2024
Correlation Between the Use of Vesicant Medications and The Incidence of Phlebitis in Pediatric Ward.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Symptomatic and pathological features in chemical phlebitis rat model by injection vinorelbine via dorsal pedal vein.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phlebitis is an inflammatory process that is characterized by inflamed venous endothelial cells. Vesicant medications are found to be one of the causes of phlebitis, especially in pediatric patients. Objective: To investigate the correlation between the use of vesicant medications and phlebitis incidence. Material and Methods: The study was descriptive observational conducted over the period of June-July 2022 in a pediatric ward. The inclusion criteria were male or female pediatric inpatients, aged 1 month-18 years, and receiving medication via intravenous infusion for >24 hours. The data obtained were then analyzed for correlations by using bivariate and multivariate analysis. Results and Conclusion: A total of 174 patients met the inclusion criteria; 27.6% experienced phlebitis, and 37.9% received vesicant medications. The most frequently used vesicant medications in the pediatric ward was gentamicin (74.24%). The use of vesicants and administration of >3 intravenous drugs showed statistically significant results associated with the incidence of phlebitis, with RR: 4.17 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.